At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Niraparib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
In Brief
A Phase 2 clinical trial evaluating Niraparib and Dostarlimab for Head and Neck Cancer. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartNov 2020
Primary CompletionJun 2025
Study CompletionMar 2026
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartNov 4, 2020
Primary CompletionJun 1, 2025
Study CompletionMar 4, 2026
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 6.3 years ago
Interventions
Niraparibdrug
Niraparib \& Dostarlimab combination
Dostarlimabdrug
Niraparib \& Dostarlimab combination